Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)-Reference-Cited by-同舟云学术

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

Published:2024-03 Issue:3 Volume:9 Page:102388
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Villacampa G.^ORCID,Pascual T.,Brasó-Maristany F.,Paré L.,Martínez-Sáez O.,Cortés J.^ORCID,Ciruelos E.,Martin M.,Conte P.,Carey L.A.^ORCID,Fernandez A.^ORCID,Harbeck N.,Marín-Aguilera M.,Vivancos A.,Curigliano G.^ORCID,Villagrasa P.^ORCID,Parker J.S.,Perou C.M.^ORCID,Prat A.^ORCID,Tolaney S.M.^ORCID

Funder

National Cancer Institute

Publisher

Elsevier BV

Reference34 articles.

1. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials;Lancet Oncol,2021

2. Dissecting the biological heterogeneity of HER2-positive breast cancer;Schettini;Breast,2021

3. Current and future management of HER2-positive metastatic breast cancer;Martínez-Sáez;JCO Oncol Pract,2021

4. PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?;Pondé;NPJ Breast Cancer,2019

5. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial;Pivot;Lancet,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial;Clinical Cancer Research;2024-07-12